ニューヨークにおけるバーキットリンパ腫の臨床試験
ニューヨーク内の拠点で、バーキットリンパ腫に関する20件の研究が参加者を募集しています。
ニューヨーク内の都市
- New York City14件の研究
- Buffalo8件の研究
- Greenburgh7件の研究
- The Bronx6件の研究
- Queens6件の研究
- Albany4件の研究
- Syracuse4件の研究
- Rochester4件の研究
公式研究テキスト（英語）
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- NYU Langone Hospital - Long Island, Mineola
- 他9件
被験者募集中第2相
366 Days – 46 Years · 全性別 · 2026/10/02更新 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Roswell Park Cancer Institute, Buffalo
- Northwell Health/Center for Advanced Medicine, Lake Success
- North Shore University Hospital, Manhasset
- 他4件
被験者募集中第3相
18歳〜39歳 · 全性別 · 2026/10/02更新 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Northwell Health/Center for Advanced Medicine, Lake Success
- North Shore University Hospital, Manhasset
- Long Island Jewish Medical Center, New Hyde Park
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
- 他7件
被験者募集中第2相
365 Days · 全性別 · 2026/09/25更新 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- David H. Koch Center for Cancer Care, New York
- Montefiore Medical Center PRIME, The Bronx
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中第3相
1歳以上 · 全性別 · 2026/09/17更新 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
- New York Medical College ( Site 1023), Valhalla
被験者募集中第1/2相
6 Months – 25 Years · 全性別 · 2026/09/17更新 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- The Mount Sinai Hospital, New York
被験者募集中第1相
0歳〜18歳 · 全性別 · 2026/09/16更新 · NCT06173518Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- NYU Langone Hospital - Long Island, Mineola
- 他7件
被験者募集中第2相
1歳〜30歳 · 全性別 · 2026/09/01更新 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- 他12件
被験者募集中第3相
365 Days – 25 Years · 全性別 · 2026/08/25更新 · NCT03959085AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, New York
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/08/19更新 · NCT06137118Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- New York Medical College, Valhalla
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
- New York Medical Center, Valhalla
被験者募集中第1/2相
12歳〜70歳 · 全性別 · 2026/04/15更新 · NCT04491370Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中第2相
18歳〜54歳 · 全性別 · 2026/03/17更新 · NCT06918431Study of SGR-1505 in Mature B-Cell Neoplasms
- Roswell Park Comprehensive Cancer Center, Buffalo
- Weill Cornell, New York
- Montefiore Medical Center, The Bronx
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- Roswell Park Comprehensive Cancer Center, Buffalo
被験者募集中第1相
18歳以上 · 全性別 · 2025/11/04更新 · NCT03595917Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Roswell Park Comprehensive Cancer Center, Buffalo
- Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
被験者募集中第1/2相
15歳〜50歳 · 全性別 · 2025/09/09更新 · NCT04150497Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
- New York Medical College, Valhalla
被験者募集中第2相
3歳〜31歳 · 全性別 · 2025/08/08更新 · NCT02393157The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Roswell Park Cancer Institute, Buffalo
被験者募集中第2相
1歳〜25歳 · 全性別 · 2025/05/04更新 · NCT03509961ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。